<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927963</url>
  </required_header>
  <id_info>
    <org_study_id>AJIRB-MED-OBS-18-478</org_study_id>
    <nct_id>NCT03927963</nct_id>
  </id_info>
  <brief_title>The Neuroprotection Effect of Dexmedetomidine</brief_title>
  <official_title>The Anti-inflammatory Effect and Hemodynamic Stability of Dexmedetomidine in Aneurysmal Clipping Operation; Compare With Propofol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The brain protection effect of dexmedetomidine has been approved in several studies.

      Basically, the anti-inflammatory effects and reducing catecholamines are thought to be a main
      role of the protection effect. In many studies reported the advantage of dexmedetomidine as a
      substitution of other sedative drugs for anesthesia.

      The anesthesia of intra-cranial aneurysmal clipping operation commonly use intravenous
      anesthetic agents combined with inhalation anesthesia for neuroprotection, and mostly
      propofol is used.

      The aim of this study is to examine the effects of dexmedetomidine on serum inflammatory
      markers and research the hemodynamic stability of dexmedetomidine compared to propofol in
      aneurysmal clipping operation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The concentration of inflammatory markers</measure>
    <time_frame>Baseline: Before injection study drugs</time_frame>
    <description>CRP (mg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of inflammatory markers</measure>
    <time_frame>1 minute after operation</time_frame>
    <description>CRP (mg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of inflammatory markers</measure>
    <time_frame>Day 1 after operation</time_frame>
    <description>CRP (mg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of inflammatory markers</measure>
    <time_frame>Day 2 after operation</time_frame>
    <description>CRP (mg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of norepinephrine</measure>
    <time_frame>Baseline: Before injection study drugs</time_frame>
    <description>NE (nmol/l)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of norepinephrine</measure>
    <time_frame>1 minute after operation</time_frame>
    <description>NE (nmol/l)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of norepinephrine</measure>
    <time_frame>Day 1 after operation</time_frame>
    <description>NE (nmol/l)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of norepinephrine</measure>
    <time_frame>Day 2 after operation</time_frame>
    <description>NE (nmol/l)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of inflammatory markers</measure>
    <time_frame>Baseline: Before injection study drugs</time_frame>
    <description>IL-6, IL-8, IL-10 ,TNF-a (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of inflammatory markers</measure>
    <time_frame>1 minute after operation</time_frame>
    <description>IL-6, IL-8, IL-10 ,TNF-a (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of inflammatory markers</measure>
    <time_frame>Day 1 after operation</time_frame>
    <description>IL-6, IL-8, IL-10 ,TNF-a (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of inflammatory markers</measure>
    <time_frame>Day 2 after operation</time_frame>
    <description>IL-6, IL-8, IL-10 ,TNF-a (pg/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The frequency of hypotension or hypertension</measure>
    <time_frame>during operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Dexmedetomidine</condition>
  <arm_group>
    <arm_group_label>propofol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine 0.7 ug/kg/h with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period</description>
    <arm_group_label>dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Effect site concentration of propofol 1.5 ng/ml with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period</description>
    <arm_group_label>propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA class I,II patient needs operation of intracranial aneurysmal clipping without SAH

        Exclusion Criteria:

          -  Any history of neurologic disease, dementia

          -  Allergic history of propofol or dexmedetomidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiyoung Yoo</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

